Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin not reported for Q1 FY2026
Context
- Operating margin widened in 1 of the last 2 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of -1323.5% for the fiscal year ending Dec 2026, up from -2113.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -2113.8%+1163.9 pp YoY
- LTMMar 2026
- —— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +1163.9 pp | +790.3 pp | -373.6 pp |
| 3 years | — | +2001.3 pp | — |
| 5 years | +2109.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -2113.8%
- Year-over-year change
- +1163.9pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -2113.8% | +1163.9pp |
| FY2024 | 2024-12-31 | -3277.8% | -3203.5pp |
| FY2023 | 2023-12-31 | -74.3% | — |
| FY2022 | 2022-12-31 | — | — |
Operating Margin vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's FY2025 operating margin of -2113.8% is the 3rd highest of the 5 companies compared; the peer median is -3069.2%.
- Its year-over-year change of +1163.9 pp is the highest of 3, against a peer median of -608.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 39.8% | — | +621.2 pp | |
| LTM Mar 2026 | -961.9% | -168.3 pp | -673.9 pp | |
| FY2025 | -2113.8% | +1163.9 pp | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -5176.5% | -1049.1 pp | -3646.1 pp |
| LTM Sep 2026 | -7488.4% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ZBIO) | -3069.2% | -608.7 pp | -673.9 pp | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| Weighted Avg Shares | 38.32M | 38.32M | 41.79M | 44.73M |
| Weighted Avg Shares (Diluted) | 38.32M | 38.32M | 41.79M | 44.73M |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.